Affymetrix, Inc. : Affymetrix Announces Research Collaboration with Massachusetts General Hospital to Validate and Develop New Oncology Biomarker Tests
06/06/2012| 07:35am US/Eastern
Inc. (NASDAQ:AFFX) today announced a research collaboration and
licensing agreement with Massachusetts General Hospital (MGH) to
co-develop new cancer biomarker tests using the Affymetrix' QuantiGene®
ViewRNA Assay platform*, an in situ hybridization assay
capable of single transcript in single-cell detection. As part of this
agreement, Affymetrix has the rights to commercialize the new biomarker
tests as an outcome of this collaboration.
"This agreement provides Affymetrix with an important opportunity to
expand its QuantiGene ViewRNA Assay offering into the pathology and
cancer research markets by providing new multiplex chromogenic in situ
hybridization (CISH) and fluorescence in situ hybridization
(FISH) RNA biomarker assays which are validated on clinical samples for
research applications. Advanced in situ RNA hybridization methods
applied to less invasive clinical samples such as FFPE core biopsies,
FNAs, and CTCs has the potential of becoming powerful new tools to
deliver diagnostics that enable the oncologist to personalize patient
care," stated George Bers, Vice President and General Manager, Gene
Expression Business Unit Manager - Panomics at Affymetrix.
Currently, those who practice surgical pathology and cytology face
challenges in the management of a broad range of cancers. Medical
practitioners are optimistic that a solution to these challenges will be
found in new biomarkers and drug targets which are being rapidly
discovered by NGS and microarray technologies. Yet these new biomarker
discoveries have in themselves become a challenge requiring extensive
validation prior to becoming candidates for translation into diagnostic,
prognostic, and predictive tests to fulfill the promise of delivering a
new generation of personalized medicine and associated economic and
"The future of cancer treatment lies in our ability to precisely
identify specific biomarkers so we can then find effective drugs for
that particular form of disease," said Daniel A. Haber, MD, PhD,
director of the MGH Cancer Center. "This collaboration with Affymetrix
aims to move this important work forward."
MGH is a world leader in cancer research and education, translational
medicine, and a major center for patient care. MGH has some of the
world's largest annotated tissue banks for retrospective biomarker
studies as well as large and diverse patient populations for prospective
studies. MGH's Cancer Center and Department of Pathology are currently
collaborating with Affymetrix to validate biomarkers of current and
future clinical importance using Affymetrix' QuantiGene ViewRNA
technology platform for multiplex in situ testing of FFPE tissue
biopsies, FNA cytologies, and CTC "liquid biopsies". QuantiGene ViewRNA
is an ideal platform for cancer biomarker validation and testing as RNA
is a predictable, sensitive and specific alternative to antibody based
IHC and ICC testing. QuantiGene ViewRNA probes for RNA assays can be
developed for research applications for any expressed gene within days
and can analyze non-coding RNAs believed to be important master
regulators of cancer and for which antibody assays can't be developed.
To date, the research collaboration has produced several potential
diagnostic/prognostic biomarker targets including new class of
non-coding RNA, HSATII, and EGFR vIII.
* For Research Use Only. Not for use in diagnostic procedures.
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading academic,
government, and nonprofit research institutes. More than 25,000
peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Santa Clara, Cleveland, Ohio, and Singapore.
The company has about 900 employees worldwide and maintains sales and
distribution operations across Europe, Asia, and Latin America. For more
information about Affymetrix, please visit http://www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions,"
"strategies" or the like. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially for
Affymetrix from those projected. These and other risk factors are
discussed in Affymetrix' Form 10-K for the year ended December 31, 2010,
and other SEC reports for subsequent quarterly periods.
PLEASE NOTE: Affymetrix, the Affymetrix logo, GeneChip,
QuantiGene and all other trademarks are the property of Affymetrix, Inc.
All other trademarks are the property of their respective owners.
Mindy Lee-Olsen, 408-731-5523 (Media)
President, Marketing Services
Farrell, 408-731-5285 (Investors)
Vice President, Investor Relations
© Business Wire 2012